# A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

> **NCT02365662** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 46 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Non-small Cell Lung Cancer
- Triple Negative Breast Cancer
- Colorectal Carcinoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** ABBV-221

## Key facts

- **NCT ID:** NCT02365662
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-09
- **Primary completion:** 2018-03-15
- **Final completion:** 2018-03-15
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Safety
- **Last updated:** 2018-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365662, "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02365662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*